Medikine, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.medikine.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
1 Phases
Phase 1:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (100.0%)A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Phase 1
Terminated
- Conditions
- Advanced or Metastatic Solid Tumors
- Interventions
- Drug: Checkpoint Inhibitor, Immune
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Medikine, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05716295
- Locations
- 🇺🇸
Sarah Cannon Research Institute (Florida Cancer Specialists), Sarasota, Florida, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
🇺🇸NEXT Oncology Austin, Austin, Texas, United States
A Single Ascending Dose Study to Evaluate MDK-703 in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy Volunteers
- First Posted Date
- 2022-05-09
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Medikine, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05366634
- Locations
- 🇦🇺
Medikine Clinical Site, Herston, Queensland, Australia
News
No news found